IL-2R beta/common gamma chain antibodies
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
1. An isolated antibody or antigen binding fragment, which specifically binds to CD122 and common γ chain (γc), wherein the antibody or antigen binding fragment is an IL-2 receptor agonist, and wherein the antibody or antigen-binding fragment comprises:
(a) an antigen-binding fragment which binds to CD122, comprising:
(i) a light chain variable region comprising the
following CDRs:
LC-CDR1:
(SEQ ID NO: 2)
TGTSSDIGHYDFVS
LC-CDR2:
(SEQ ID NO: 3)
DINNRPS
LC-CDR3:
(SEQ ID NO: 4)
SAYTSSDTLV;
and
(ii) a heavy chain variable region comprising the
following CDRs:
HC-CDR1:
(SEQ ID NO: 36)
NYYMH
HC-CDR2:
(SEQ ID NO: 37)
AIMPSRGGTSYPQKFQG
HC-CDR3:
(SEQ ID NO: 38)
GEYYYDSSGYYY;
and
(b) an antigen-binding fragment which binds to common γ chain, comprising:
(i) a light chain variable region comprising the
following CDRs:
LC-CDR1:
(SEQ ID NO: 68)
RSSQSLLHSNGYNYLD
LC-CDR2:
(SEQ ID NO: 69)
LGSNRDS
LC-CDR3:
(SEQ ID NO: 70)
MQGTHWPWT;
and
(ii) a heavy chain variable region comprising the
following CDRs:
HC-CDR1:
(SEQ ID NO: 48)
GYYWS
HC-CDR2:
(SEQ ID NO: 49)
EINHSGSTNYNPSLKS
HC-CDR3:
(SEQ ID NO: 77)
SPGGYSGGYFQH.
2. The isolated antibody or antigen binding fragment according to claim 1 , wherein the antigen-binding fragment which binds to CD122 comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 70% sequence identity to the light chain variable region sequence of SEQ ID NO:1, and
the heavy chain variable region sequence has at least 70% sequence identity to the heavy chain variable region sequence of SEQ ID NO:35.
3. The isolated antibody or antigen binding fragment according to claim 1 , wherein the antigen-binding fragment which binds to common γ chain comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 70% sequence identity to the light chain variable region sequence of SEQ ID NO:67, and
the heavy chain variable region sequence has at least 70% sequence identity to the heavy chain variable region sequence of SEQ ID NO:76.
4. The isolated antibody or antigen binding fragment according to claim 1 , which binds to the IL-2 receptor comprising a complex of CD122 and common γ chain.
5. The isolated antibody or antigen binding fragment according to claim 1 , provided in scFv-KiH-Fc or CrossMab format.
6. The isolated antibody or antigen binding fragment according to claim 1 , conjugated to a drug moiety or a detectable moiety.